Multiple sclerosis treatment and infectious issues: Update 2013

Clinical and Experimental Immunology

Volumn 175, Issue 3, 2014, Pages 425-438

  Winkelmann, A ^a   Loebermann, M ^a   Reisinger, E C ^a   Zettl, U K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Disease modifying treatment; Immunosuppression; Infection; Multiple sclerosis; Side effects

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB; TERIFLUNOMIDE;

ARTICLE; DISEASE SEVERITY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; LONG TERM CARE; MULTIPLE SCLEROSIS; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RELAPSE;

DISEASE-MODIFYING TREATMENT; IMMUNOSUPPRESSION; INFECTION; MULTIPLE SCLEROSIS; SIDE EFFECTS;

HUMANS; IMMUNOLOGIC FACTORS; INFECTION; INFECTION CONTROL; MULTIPLE SCLEROSIS;

EID: 84893349529     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12226     Document Type: Article

References (141)

1. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013; doi: 10.1016/j.jns.2013.05.010.
2. Lucchinetti CF, Popescu BF, Bunyan RF etal. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365:2188-2197.
3. Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11:167-173.
4. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010; 33:140-152.
5. Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis 2013; 4:45-51.
6. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2011; 10:1026-1034.
7. Meuth SG, Gobel K, Wiendl H. Immune therapy of multiple sclerosis - future strategies. Curr Pharm Des 2012; 18:4489-4497.
8. Mulakayala N, Rao P, Iqbal J, Bandichhor R, Oruganti S. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Eur J Med Chem 2013; 60:170-186.
9. Rommer PS, Zettl UK, Kieseier B etal. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 2014; 175:397-407.
10. Abinun M. An overview of infectious complications in children on new biologic response-modifying agents. Pediatr Health 2010; 4:509-517.
11. Goodin DS, Frohman EM, Garmany GP Jr etal. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169-178.
12. Filippini G, Brusaferri F, Sibley WA etal. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; doi: 10.1002/14651858.cd001331.
13. Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol 2013; doi: 10.3389/fneur.2013.00021.
14. Pirko I, Rodriguez M. Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial. Arch Neurol 2004; 61:1148-1149.
15. Goodkin DE, Kinkel RP, Weinstock-Guttman B etal. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51:239-245.
16. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010; 125:S195-203.
17. Schweingruber N, Reichardt SD, Luhder F, Reichardt HM. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol 2012; 24:174-182.
18. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275:71-78.
19. Spies CM, Bijlsma JW, Burmester GR, Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010; 10:302-307.
20. Weinshenker BG, O'Brien PC, Petterson TM etal. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886.
21. Keegan M, Konig F, McClelland R etal. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366:579-582.
22. Multiple Sclerosis Therapy Consensus Group, Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255:1449-1463.
23. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011; 1812:239-245.
24. Matzke B, Metze C, Winkelmann A etal. Severe relapse of multiple sclerosis during plasma exchange treatment. Mult Scler 2011; 17:759-762.
25. Zettl UK, Hartung HP, Pahnke A, Brueck W, Benecke R, Pahnke J. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 2006; 67:1515-1516.
26. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63:930-935.
27. Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980; 244:2423-2426.
28. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23:817-827.
29. Haugh PJ, Levy CS, Smith MA, Walshe DK. Nosocomial Neisseria meningitidis sepsis as a complication of plasmapheresis. Clin Infect Dis 1996; 22:1116-1117.
30. Vucic S, Davies L. Safety of plasmapheresis in the treatment of neurological disease. Aust NZ J Med 1998; 28:301-305.
31. Kaneko S, Sata M, Ide T etal. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatol Res 2010; 40:1072-1081.
32. Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis. Transfusion 2004; 44:1621-1625.
33. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39:350-354.
34. Bouget J, Chevret S, Chastang C, Raphael JC. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group. Crit Care Med 1993; 21:651-658.
35. Boucher CA, de Gans J, van Oers R, Danner S, Goudsmit J. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barre syndrome. Clin Neurol Neurosurg 1988; 90:235-236.
36. Fensterl V, Sen GC. Interferons and viral infections. Biofactors 2009; 35:14-20.
37. Hundeshagen A, Hecker M, Paap BK etal. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation 2012; doi: 10.1186/1742-2094-9-140.
38. Hecker M, Goertsches RH, Fatum C etal. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 2012; 12:360.
39. Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 1998; 160:4386-4397.
40. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125:2381-2391.
41. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102:6449-6454.
42. Johnson KP, Brooks BR, Cohen JA etal. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-1276.
43. Johnson KP, Brooks BR, Cohen JA etal. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50:701-708.
44. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2012; 12:371-384.
45. Karussis D. Immunotherapy of multiple sclerosis: the state of the art. BioDrugs 2013; 27:113-148.
46. O'Sullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmacol Sci 2013; 34:401-412.
47. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69:759-777.
48. Kappos L, Radue EW, O'Connor P etal. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
49. Cohen JA, Barkhof F, Comi G etal. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
50. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Fingolimod treatment for multiple sclerosis patients. What do we do with varicella? Ann Neurol 2011; 70:673-674; author reply 4.
51. Gold R, Kappos L, Arnold DL etal. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098-1107.
52. Fox RJ, Miller DH, Phillips JT etal. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087-1097.
53. EMA. Tecfidera (web page), 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002601/WC500140695.pdf (accessed 29 April 2013).
54. Food and Drug Administration (FDA). FDA approves new multiple sclerosis treatment: Tecfidera (web page), 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345528.htm (accessed 23 August 2013).
55. Altmeyer PJ, Matthes U, Pawlak F etal. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30:977-981.
56. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 2012; 142:44-48.
57. Kappos L, Gold R, Miller DH etal. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
58. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368:1657-1658.
59. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368:1658-1659.
60. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med 2013; 368:1659-1661.
61. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) [Federal Institute for Drugs and Medical Devices]. Adverse events database, query words: "Fumaderm" and "Progressive Multifokale Lekenzephalopathie", 2013. Available at: http://www.bfarm.de/DE/Pharmakovigilanz/uaw-db/uaw-db-node.html (accessed 22 April 2013).
62. Fox RI, Herrmann ML, Frangou CG etal. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93:198-208.
63. Food and Drug Administration (FDA). FDA approves new multiple sclerosis treatment Aubagio, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm (accessed 12 August 2013).
64. European Medicines Agency (EMA). Aubagio (web page), 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002514/WC500140690.pdf (accessed 20 August 2013).
65. O'Connor P, Wolinsky JS, Confavreux C etal. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293-1303.
66. Oh J, O'Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manage 2013; 9:177-190.
67. O'Connor PW, Li D, Freedman MS etal. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894-900.
68. Confavreux C, Li DK, Freedman MS etal. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012; 18:1278-1289.
69. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011; 306:173-179.
70. Brunmark C, Runstrom A, Ohlsson L etal. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130:163-172.
71. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol 2010; 221:87-94.
72. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MSSG. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64:987-991.
73. Comi G, Pulizzi A, Rovaris M etal. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
74. Comi G, Jeffery D, Kappos L etal. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366:1000-1009.
75. ®), 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT00605215 (accessed 20 August 2013).
76. Comi G, Abramsky O, Arbizu T etal. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 2010; 16:1360-1366.
77. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7:538-547.
78. Rommer PS, Patejdl R, Zettl UK. Monoclonal antibodies in the treatment of neuroimmunological diseases. Curr Pharm Des 2012; 18:4498-4507.
79. Tony HP, Burmester G, Schulze-Koops H etal. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13:R75.
80. Coles AJ, Wing M, Smith S etal. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691-1695.
81. Coles AJ, Cox A, Le Page E etal. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253:98-108.
82. ClinicalTrials. A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis. NCT01412333, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01412333?term=NCT01412333&rank=1 (accessed 24 April 2013).
83. ClinicalTrials. A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis NCT01247324, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01247324?term=NCT01247324&rank=1 (accessed 20 August 2013).
84. ClinicalTrials. A study of ocrelizumab in patients with primary progressive multiple sclerosis NCT01194570, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01194570?term=NCT01194570&rank=1 (accessed 24 April 2013).
85. ClinicalTrials. Ofatumumab dose-finding in relapsing remitting multiple sclerosis (RRMS) patients (OMS115102) NCT00640328, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT00640328?term=NCT00640328&rank=1 (accessed 24 April 2013).
86. ClinicalTrials. Ofatumumab subcutaneous administration in subjects with relapsing-remitting multiple sclerosis (MIRROR) NCT01457924, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01457924?term=NCT01457924&rank=1 (accessed 29 April 2013).
87. Deiss A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013; 13:313-335.
88. Leger OJ, Yednock TA, Tanner L etal. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8:3-16.
89. Hutchinson M, Kappos L, Calabresi PA etal. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256:405-415.
90. Havrdova E, Galetta S, Hutchinson M etal. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8:254-260.
91. Rudick RA, Stuart WH, Calabresi PA etal. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911-923.
92. Warnke C, Menge T, Hartung HP etal. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010; 67:923-930.
93. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
94. Brickelmaier M, Lugovskoy A, Kartikeyan R etal. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840-1849.
95. Elphick GF, Querbes W, Jordan JA etal. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380-1383.
96. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66:255-258.
97. Schroder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67:1391-1394.
98. Sorensen PS, Bertolotto A, Edan G etal. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18:143-152.
99. Bloomgren G, Richman S, Hotermans C etal. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366:1870-1880.
100. Biogen Idec. TYSABRI® (natalizumab) injection - full prescribing information, 2012. Available at: http://www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf (accessed 7 October 2013).
101. Cox AL, Thompson SA, Jones JL etal. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35:3332-3342.
102. Jones JL, Phuah CL, Cox AL etal. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052-2061.
103. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30:99-105.
104. Cohen JA, Coles AJ, Arnold DL etal. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819-1828.
105. Coles AJ, Twyman CL, Arnold DL etal. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829-1839.
106. European Medicines Agency (EMA). Summary of opinion 1. Lemtrada (Alemtuzumab), 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003718/WC500144904.pdf (accessed 23 August 2013).
107. Hauser SL, Waubant E, Arnold DL etal. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688.
108. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med 2011; 9:36.
109. Carbone J, del Pozo N, Gallego A, Sarmiento E. Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther 2011; 9:405-413.
110. Hawker K, O'Connor P, Freedman MS etal. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460-471.
111. Bielekova B, Howard T, Packer AN etal. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66:483-489.
112. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10:55-67.
113. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69:785-789.
114. Wynn D, Kaufman M, Montalban X etal. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381-390.
115. Liu J, Wang L, Zhan SY, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2012; (4):CD008127.
116. Gold R, Giovannoni G, Selmaj K etal. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:2167-2175.
117. ClinicalTrials. Safety and efficacy study of daclizumab HYP to treat relapsing-remitting multiple sclerosis (SELECT) NCT00390221, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT00390221?term=NCT00390221&rank=1 (accessed 20 August 2013).
118. ClinicalTrials. A multicenter, open-label, extension study to evaluate the long term safety and efficacy of daclizumab high yield process (DAC HYP) monotherapy in subjects with multiple sclerosis who have completed treatment in study 205MS202 (SELECTION) NCT01051349, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01051349?term=NCT01051349&rank=1 (accessed 20 August 2013).
119. ClinicalTrials. Efficacy and safety of daclizumab high yield process versus interferon β 1a in patients with relapsing-remitting multiple sclerosis (DECIDE) NCT01064401, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01064401?term=NCT01064401&rank=1 (accessed 20 August 2013).
120. ClinicalTrials. An immunogenicity and pharmacokinetics (PK) study of DAC HYP prefilled syringe in relapsing remitting multiple sclerosis (RRMS) (OBSERVE) NCT01462318, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01462318?term=NCT01462318&rank=1 (accessed 20 August 2013).
121. ClinicalTrials. Long-term extension study in subjects with multiple sclerosis who have completed study 205MS301 (NCT01064401) to evaluate the safety and efficacy of DAC HYP (EXTEND) NCT01797965, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01797965?term=NCT01797965&rank=1 (accessed 29 April 2013).
122. Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Curr Opin Neurol 2011; 24:217-223.
123. Gold R, Stangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3:36-44.
124. Winkelmann A, Zettl UK. Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system. Curr Pharm Des 2012; 18:4570-4582.
125. Boschetti N, Stucki M, Spath PJ, Kempf C. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol 2005; 29:333-344.
126. Awad A, Stüve O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord 2009; 2:50-61.
127. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics, Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463-1470.
128. Rieckmann P, Toyka KV, Bassetti C etal. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J Neurol 2004; 251:1329-1339.
129. Boster A, Edan G, Frohman E etal. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008; 7:173-183.
130. Kappos L, Polman CH, Freedman MS etal. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242-1249.
131. Kappos L. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:1491-1497.
132. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788-1795.
133. Johnson KP. A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data. J Neurol 1996; 243:S3-7.
134. Uccelli A, Ginocchio F, Mancardi GL, Bassetti M. Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011; 76:1023-1024.
135. Biogen. Tysabri (web page), 2013. Available at: http://www.Tysabri.de (accessed 06 May 2013).
136. Cohen SB, Emery P, Greenwald MW etal. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
137. Edwards JC, Szczepanski L, Szechinski J etal. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
138. Emery P, Fleischmann R, Filipowicz-Sosnowska A etal. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400.
139. Anonymous. Reversibles Kaposi-Sarkom unter Fumaderm®-assoziierter Lymphozytopenie [Reversible Kaposi sarcoma during Fumaderm (R)-associated lymphocytopenia]. Dtsch Arztebl 2009; 106:A2380.
140. Anonymous. Nokardiose bei Lymphopenie durch Fumaderm [Nokardia infection in Fumaderm (R) associated Lymphycytopenia]. Dtsch Arztebl 2013; 110:A1220.
141. Biogen. Wichtige Mitteilung an medizinische Fachkreise: Fumaderm® initial/Fumaderm®, 2013. Available at: http://www.bfarm.de/SharedDocs/1_Downloads/DE/Pharmakovigilanz/roteHandBriefe/2013/rhb-fumaderm.pdf;jsessionid=EF2AFF7888678D05032D371129B12089.1_cid332?__blob=publicationFile (accessed 8 August 2013).